Literature DB >> 22429316

The use of prisms for vision rehabilitation after macular function loss: an evidence-based review.

Samuel N Markowitz1, Sophia V Reyes, Li Sheng.   

Abstract

To determine the efficacy of prisms used for redirection of incoming images towards the peripheral retina in cases with macular function loss. Meta-analysis of published work reporting outcomes from interventions using prisms was performed. The primary outcome measure selected for analysis was visual acuity (VA) used for viewing distance targets. Pooled data from 449 cases where prisms were prescribed for wearing in distance glasses were analysed. Visual acuity was better after using prisms (1.05 versus 0.89 logMAR units, p < 0.044). Mean effect size for improving VA was 79 bigger than the effect size calculated for the control group (0.158 versus 0.002). Most patients (76%) reported compliance with the therapy and also reported other benefits directly derived from the realized VA improvement. Published studies collectively offer positive evidence in support of using prisms for low vision rehabilitation after macular function loss. Further research is required to reach definitive binding conclusions.
© 2012 The Authors. Acta Ophthalmologica © 2012 Acta Ophthalmologica Scandinavica Foundation.

Entities:  

Mesh:

Year:  2012        PMID: 22429316     DOI: 10.1111/j.1755-3768.2011.02336.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN: 1755-375X            Impact factor:   3.761


  3 in total

Review 1.  Reading aids for adults with low vision.

Authors:  Gianni Virgili; Ruthy Acosta; Lori L Grover; Sharon A Bentley; Giovanni Giacomelli
Journal:  Cochrane Database Syst Rev       Date:  2013-10-23

Review 2.  Reading aids for adults with low vision.

Authors:  Gianni Virgili; Ruthy Acosta; Sharon A Bentley; Giovanni Giacomelli; Claire Allcock; Jennifer R Evans
Journal:  Cochrane Database Syst Rev       Date:  2018-04-17

3.  Scotoma Simulation in Healthy Subjects.

Authors:  Sascha Klee; Dietmar Link; Stefan Sinzinger; Jens Haueisen
Journal:  Optom Vis Sci       Date:  2018-12       Impact factor: 1.973

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.